Eli Lilly Acquisition of Calytrix Bio, Digi Mart USA News: Eli Lilly and Co has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, according to a publisher report. The deal is structured as a definitive agreement under which Calytrix shareholders will receive an upfront payment followed by additional payments tied to clinical and regulatory milestones.
The companies have not disclosed the size of the initial payment or an expected completion date for the transaction. Eli Lilly shares were up more than 1% at $1,466.58 in New York trading on Monday morning, the report said.
The acquisition centres on Calytrix’s lead experimental programme, a preclinical antibody designed to treat essential thrombocythemia and myelofibrosis driven by mutations in the calreticulin protein. Both conditions belong to a group of diseases called myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of abnormal blood cells.
The antibody is designed to target both Type 1 and Type 2 mutant calreticulin, with the aim of eliminating disease-driving cells while preserving healthy tissue and blood-cell production. Calytrix said existing drug treatments for these conditions mainly manage symptoms and complications, which it sees as an opportunity for therapies that act on the underlying mutations and could potentially alter the course of the diseases.
The programme remains at the preclinical stage and must undergo clinical development before its safety and effectiveness in patients can be established. Calytrix chief executive Brad Prosek said the company was founded to develop treatments that could do more than manage symptoms and welcomed Lilly’s plans to advance the programme through clinical trials.
The acquisition broadens Lilly’s presence in the myeloproliferative neoplasm field and builds on its existing blood cancer portfolio, which includes the approved treatment Jaypirca. Calytrix was founded in 2025 by JP Morgan Life Sciences Private Capital and later received backing from Westlake BioPartners and Avoro Ventures.











